Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Revenue of $7.4 million for Q1 2026, down 91.36% year-on-year from $85.3 million in Q1 2025, and down 99.28% on a QoQ basis from $1.0 billion in Q4 2025.
Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Revenue for 13 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.
- Quarterly Revenue fell 91.36% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 365.55% YoY) and the FY2025 annual result came in at $1.3 billion, up 303.5% from the prior year.
- Revenue declined to $7.4 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
- Over the last five years, Revenue for LKFT reached as high as $1.0 billion in Q4 2025 and fell as low as -$58.2 million in Q2 2024.
- A 5-year average of $124.8 million and a median of $69.6 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue tumbled 185.24% — and 2025, when it soared 7733.23%.
- Year by year, Revenue stood at $205.7 million in 2022, then slumped by 37.87% to $127.8 million in 2023, then slumped by 89.76% to $13.1 million in 2024, then surged by 7733.23% to $1.0 billion in 2025, then sank by 99.28% to $7.4 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $7.4 million, $1.0 billion, and $81.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.51 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.38 Mn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 80.98 Mn |
| Jun 30, 2025 | 74.29 Mn |
| Mar 31, 2025 | 85.32 Mn |
| Dec 31, 2024 | 13.09 Mn |
| Sep 30, 2024 | 214.95 Mn |
| Jun 30, 2024 | -58.23 Mn |
| Mar 31, 2024 | 71.04 Mn |
| Dec 31, 2023 | 127.79 Mn |
| Sep 30, 2023 | 69.62 Mn |
| Jun 30, 2023 | 68.31 Mn |
| Mar 31, 2023 | 66.65 Mn |
| Dec 31, 2022 | 205.69 Mn |
| Sep 30, 2022 | 28.55 Mn |
| Jun 30, 2022 | 23.88 Mn |
| Mar 31, 2022 | 16.40 Mn |
| Dec 31, 2021 | 259.78 Mn |
| Sep 30, 2021 | 6.94 Mn |
| Jun 30, 2021 | 159.05 Mn |